Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Influenza-associated morbidity and mortality has not decreased in the last decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza vaccine, a high-dose (HD) trivalent, inactivated influenza vaccine was developed. METHODS: A multicenter, randomized, double-blind controlled study was conducted to compare HD vaccine (which contains 60 microg of hemagglutinin per strain) with the licensed standard-dose (SD) vaccine (which contains 15 microg of hemagglutinin per strain) in adults > or = 65 years of age. RESULTS: HD vaccine was administered to 2575 subjects, and SD vaccine was administered to 1262 subjects. There was a statistically significant increase in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vaccination among those who received HD vaccine, compared with those who received SD vaccine. Mean postvaccination titers for individuals who received HD vaccine were 116 for H1N1, 609 for H3N2, and 69 for B strain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2, and 52 for B strain. The HD vaccine met superiority criteria for both A strains, and the responses for B strain met non-inferiority criteria. Seroprotection rates were also higher for those who received HD vaccine than for those who received SD vaccine vaccine, for all strains. Local reactions were more frequent in individuals who received HD vaccine, but the reactions were mild to moderate. CONCLUSIONS: There was a statistically significant increase in the level of antibody response induced by HD influenza vaccine, compared with that induced by SD vaccine, without an attendant increase in the rate or severity of clinically relevant adverse reactions. These results suggest that the high-dose vaccine may provide improved protective benefits for older adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00391053 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of the above formulations show slightly higher immunogenicity in the elderly compared to the standard trivalent inactivated vaccine.”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [161]
In the citing paper
“for some populations, such as older adults, a higher dose might be beneficial, as has been shown for the influenza vaccine69,70.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [69]
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodInfluenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodAntibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064 · cited 2×
“vaccine effectiveness are generally lower in older adults [1, 4-6].”
BackgroundResultHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002 · cited 2×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundGovaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly
Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P., & Hak, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070844 · Cited by 656 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 543 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MAN
POTTER, C. W., & OXFORD, J. S. (1979) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071545 · Cited by 452 · cited 1×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundVu, T., Farish, S., Jenkins, M., & Kelly, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00041-5 · Cited by 376 · cited 1×
“appears that efficacy is diminished in older age groups [18].”
BackgroundThe efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Nichol, K. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00070-7 · Cited by 265
Cited by
Items 301–388 of 388
Prediction of Bacterial and Archaeal Allergenicity with AllPred Program
Олегович, Б. А., Соколов, В. С., Сергеевич, Д. П., Ivanisenko, T., Bragina, E. Y., Matushkin, Y. G., & Иванисенко, В. А. (2018) · Molecular Biology · doi:10.1134/s0026893317050041 · Cited by 4
Boukhvalova, M. S., Mortensen, E., Mbaye, A., McKay, J., & Blanco, J. C. G. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1766334 · Cited by 4
“Even though the difference between the higher and lower vaccine doses tested here (16-fold) exceeds the fourfold difference between the high-dose and standard TIV vaccine, these results experimentally confirm the observation that immunogenicity of TIV in the aged population can be boosted with the use of a higher vacc…”
ResultExploring the possible therapeutic role of influenza vaccine in chronic kidney disease patients
Shrestha, A. B., Mohammed, Y. A., Umar, T. P., Shrestha, S., Mehta, A., & Jaiswal, V. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000357 · Cited by 4
“In a randomized controlled trial by Falsey et al.[7], they stated that HDV was associated with a significant increase in antibody levels compared to SDVwithout a significant increase in relevant adverse events, which suggests that HDV has a higher protective effect.”
BackgroundLutz, M. K., & Caldera, F. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003641.08 · Cited by 5
Hannaford, A., Aleissa, M. M., & Sherman, A. C. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.010 · Cited by 6
IAPSM’s Position Paper on Influenza Vaccines for Adult Immunization in India
Sharma, N., Verma, M., Goel, K., Kulkarni, M. M., Bhardwaj, A., Sharma, S., Singh, T., Gupta, M., Nadda, A., & Sankhe, L. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_741_24 · Cited by 3
Strowd, R. E., III, Russell, G. B., Hsu, F., Carter, A. F., Chan, M. D., Tatter, S. B., Laxton, A. W., Alexander‐Miller, M. A., High, K. P., & Lesser, G. J. (2018) · Neuro-Oncology Practice · doi:10.1093/nop/npx035 · Cited by 3
Chelu, G. C., Prada, G. I., Băjenaru, O., Matei-Lincă, C.-M., Nuță, C. R., & Moscu, S.-G. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2024-0274 · Cited by 8
“Both clinical trials and post-authorization data demonstrate a good safety profile of the HD vaccine in the elderly population aged 65 years and over [87,88].”
BackgroundEspersen, C., Johansen, N. D., Modin, D., Janstrup, K. H., Nealon, J., Samson, S., Loiacono, M. M., Harris, R. C., Andrew, M. K., Larsen, C. S., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf420 · Cited by 4
“…HD-IIV has been shown to improve vaccine immunogenicity and efficacy compared with standard-dose influenza vaccination (SD-IIV) in older adults [21, 22] and could represent a promising approach to lower the risk of influenza-related complications particularly among the high-risk older, frail…”
Volling, C., Coleman, B. L., Katz, K. C., Simor, A. E., Muller, M. P., Powis, J. E., McElhaney, J. E., & McGeer, A. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.05.002 · Cited by 3
Chawansuntati, K., Chotirosniramit, N., Sugandhavesa, P., Aurpibul, L., Thetket, S., Kosashunhanan, N., Supindham, T., Kaewthip, O., Sroysuwan, P., Sirisanthana, T., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1051275 · Cited by 3
Available evidence points to low effectiveness of influenza vaccines for older people
Simonsen, L. (2010) · BMJ Evidence-Based Medicine · doi:10.1136/ebm1096 · Cited by 3
Vaccine Use in Immunocompromised Adults
Whitaker, J. A., Valles, K. A., Tosh, P. K., & Poland, G. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00009-4 · Cited by 4
Seasonal flu-vaccination in the immunocompromised burns patient
Rodger, F., & Taggart, I. (2019) · Burns · doi:10.1016/j.burns.2018.03.010 · Cited by 3
New vaccine tailored to the weakened elderly immune system
Schubert, C. (2010) · Nature Medicine · doi:10.1038/nm0210-137a · Cited by 3
High-dose influenza vaccine: enhanced protection for the elderly
Trombetta, C. M., & Montomoli, E. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596673 · Cited by 2
“…GMTs between the older adult in HD and SD groups, post-vaccination GMTs and seroconversion rates were all significantly higher in the HD group for all three strains, as observed in a previous study [32]; seroprotection rates were significantly higher for the A/H1N1 and B strains in the HD group.”
Zhao, W., Lian, R., Zhao, Y., Li, Z., Liu, M., Yang, F., Zhang, J., Tian, J., Xue, F., & Gao, Y. (2026) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2026.100870 · Cited by 2
High-dose influenza vaccination
Dalcin, D., & Kwong, J. C. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.181477 · Cited by 2
Inactivated and Recombinant Influenza Vaccines
Patel, M. M., Grohskopf, L. A., Sambhara, S. R., Belser, J. A., Katz, J. M., & Fry, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00033-5 · Cited by 5
Dobrescu, A. I., Sharifan, A., Sommer, I., Neubauer-Bruckner, C., Gadinger, A., Klerings, I., Nowak, C. P., & Gartlehner, G. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-04028 · Cited by 2
Factors Affecting the Uptake of COVID-19 Vaccine amongDubai Airport's Professionals
Taryam, M. O., Alawadhi, D., Aburayya, A., Mubarak, S., Aljasmi, M., Salloum, S. A., & Mouzaek, T. (2023) · South Eastern European Journal of Public Health · doi:10.56801/seejph.vi.224 · Cited by 23
High-dose influenza vaccination in the elderly
Foster, S. L., & Moore, W. (2010) · Journal of the American Pharmacists Association · doi:10.1331/japha.2010.10529 · Cited by 2
Vaccine Development in Special Populations
Edwards, K. M., & Creech, C. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802302-0.00007-8 · Cited by 2
Vaccin grippal haute dose : un vaccin adapté aux 65 ans et plus
Gavazzi, G., Mosnier, A., Crépey, P., & Gaillat, J. (2022) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2022.01.001 · Cited by 1
Hayden, F. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00372-9 · Cited by 2
Chiem, K., Rangel‐Moreno, J., Nogales, A., & Martínez‐Sobrido, L. (2019) · Journal of Visualized Experiments · doi:10.3791/59890-v · Cited by 2
Kafle, S., Montoya, B., Tang, L., Tam, Y. K., Muramatsu, H., Pardi, N., & Sigal, L. J. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102279 · Cited by 2
Infections virales respiratoires (hors COVID-19)
Bessis, S. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(20)30778-2 · Cited by 2
Providing Additional “Muscle” for Older Adults Through Optimal Influenza Vaccine Selection
Dougherty, J. A., & Chahine, E. B. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018772579 · Cited by 2
Wittwer, K., Zimmer, G., Rommel, M. G. E., Krebs, Y., Rezinciuc, S., Sawatsky, B., & Pfaller, C. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.02.514911 · Cited by 2
Park, H.-S., Yin, A., Zhou, W., Wenstedt, E. F. E., Jedlicka, A., Dziedzic, A., Werner, A., Fenstermacher, K., Li, H., Shea, P. J., et al. (2025) · medRxiv · doi:10.1101/2025.05.22.25328179 · Cited by 2
“…65+ years of age, antibody titers to both the standard and high dose seasonal influenza vaccine are also greater in females than males ( 15, 16 ), with greater season to season durability of immunity against influenza among older females than males, particularly in response to H3N2 and IBV…”
Treanor, J. J. (2023) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_19-1 · Cited by 3
Self-citationBelongia, E. A., Nguyen, H. Q., McClure, D. L., Lewis, N. M., Ellington, S., Flannery, B. L., & Petrie, J. G. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf563 · Cited by 1
Bernholm, K. F., Johansen, N. D., Espersen, C., Modin, D., Janstrup, K. H., Nealon, J., Samson, S., Loiacono, M. M., Harris, R. C., Larsen, C. S., et al. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05408-5 · Cited by 1
Ashraf, M., Boivin, W. A., Nguyen‐Van‐Tam, J. S., Nolan, T. M., Stein, A. N., & Russell, C. A. (2026) · Expert Review of Vaccines · doi:10.1080/14760584.2026.2667732 · Cited by 2
Moerlooze, L. D., Allen, A., Bartalesi, I., Cavaleri, M., Davenport, M. P., Gessner, B. D., Gomes, B., Hayford, K., Izu, A., Izurieta, H. S., et al. (2026) · Biologicals · doi:10.1016/j.biologicals.2026.101886 · Cited by 1
Provider knowledge of trivalent inactivated and high-dose influenza vaccines
Tewell, C., Wright, P. W., & Talbot, H. K. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.081 · Cited by 1
Vaccinations for Older Adults: An Update
Bradley, S. (2014) · Current Geriatrics Reports · doi:10.1007/s13670-014-0076-7 · Cited by 1
High-dose influenza vaccine in older adults
Wang, J. M., Vardeny, O., & Zorek, J. A. (2016) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2015.12.001 · Cited by 1
Prevention and treatment of influenza in the primary care office
Golovyan, D. M., & Mossad, S. B. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13159 · Cited by 2
Reinvigorating Influenza Prevention in US Adults Aged 65 Years and Older
Schaffner, W., Gravenstein, S., HOPKINS, R. H., & Jernigan, D. B. (2016) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000462 · Cited by 2
“In a randomized, double-blind, multicenter clinical trial of 3876 adults aged 65 years and older (mean age, 73 years), highdose vaccine elicited significantly higher antibody responses compared with standard-dose vaccine for all 3 influenza strains (A/ H1N1, A/H3N3, B).(34) The high-dose vaccine met superiority criter…”
BackgroundInfluenza Vaccines for Older Persons: Progress and Pitfalls
Neuzil, K. M., & Chen, W. H. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix285 · Cited by 1
“Head-to-head immunogenicity data support that both the high-dose influenza vaccine and the adjuvanted influenza vaccine are more immunogenic than standard-dose vaccine among persons aged ≥65 years [9, 10].”
BackgroundJi, R., Zhang, J., Liang, D., Quan, H., Wu, Y., Peng, A., Li, W., Lu, S., Zhang, X., Ke, C., et al. (2023) · Viral Immunology · doi:10.1089/vim.2023.0072 · Cited by 1
Nitsch-Osuch, A. S., Jankowski, P., Kokoszka-Paszkot, J., Kuchar, E. P., Mastalerz–Migas, A., Mitkowski, P. P., Wysocki, J., Zmysłowska, A., & Antczak, A. J. (2024) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2024.134715 · Cited by 4
Revisiting the influenza vaccine.
Foster, S. L., & Nevin-Woods, C. (2011) · PubMed · Cited by 1
The Influenza Vaccine in Elderly Persons: A Shot in the Dark?
Brookhart, M. A., & McGrath, L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.2041 · Cited by 1
Vaccination (Prophylaxis) in the Elderly
Ecarnot, F., Maggi, S., & Michel, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11390-x · Cited by 1
Beran, J., & Goad, J. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-1076-8.00011-9 · Cited by 1
Gorse, G. J., Rattigan, S. M., Kirpich, A., Simberkoff, M. S., Bessesen, M. T., Gibert, C. L., Nyquist, A., Price, C. S., Gaydos, C. A., Radonovich, L. J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab468 · Cited by 1
Self-citationSynthetic nanoparticle-based vaccines against respiratory pathogens
Ross, K. A. (2013) · Iowa State University Digital Repository (Iowa State University) · Cited by 1
Combination nanoadjuvant-based vaccine against influenza virus for older adults
Senapati, S. (2020) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-20210114-134 · Cited by 1
What every Hepatologist should Know about Swine Flu
Lankarani, K. B. (2009) · Hepatitis Monthly
Vaccination Among Hospitalized Adults in Acute Care
Vaughan, L., & Salgado, C. D. (2013) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2012.11.004
Besser Impfen – neue Wege zur gezielten Immunmodulation bei Gesunden und Immunsupprimierten
Balmer, M. L., & Berger, C. T. (2014) · Therapeutische Umschau · doi:10.1024/0040-5930/a000476
Cueno, M. E., Tamura, M., Seki, K., Ohya, M., & Ochiai, K. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.11.018 · Cited by 1
“Moreover, we hypothesize that gingivalvaccination would allow both high antigen amounts to enter and have prolonged antigen retention within the gingival tissue that could elicit a strong immune response in an elderly individual (Aspinall et al., 2007; Falsey et al., 2009; Schwendener, 2014; Watson et al., 2012).”
Improving the Efficacy of Flu Vaccine
Zuger, A. (2009) · Journal watch · doi:10.1056/jw200908110000002
Marttorelli, A. (2014) · Americanae (AECID Library)
Volling, C., McGeer, A., Coleman, B. L., Katz, K. C., Simor, A. E., Muller, M. P., Powis, J. E., & McElhaney, J. E. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv133.1458
DiazGranados, C. A., Hu, B. T., Voloshen, T., Dunning, A. J., Talbot, H. K., & Landolfi, V. A. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu052.767
Reincarnations of Influenza Virus and Challenges with the Development of a Robust Influenza Vaccine
R, G., & Govindaraju, K. (2013) · HAL
Dosing of Influenza Vaccine in Older Adults: More Is Better
Baddour, L. M. (2009) · Journal watch · doi:10.1056/id200906240000004
Review Article Suggested use of vaccines in diabetes
Misra, A., Das, A. K., Saboo, B., Basu, D., Thomas, N., Joshi, S., Unnikrishnan, A. G., Shankar, A., Krishnan, G., Ranjit Unnikrishnan, I., et al. (2012)
Chronic Obstructive Lung Disease in the Elderly
Most, J. F., & Rochester, C. L. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814635011_0014
Impfen älterer Personen: Immunologische Besonderheiten beachten
Leischker, A. H. (2019) · Deutsches Ärzteblatt · doi:10.3238/persinfek.2019.07.22.04
Continued Consideration for High Dose Influenza Vaccine in Persons Living With HIV
Jennings, S.-L., Swiderek, J., Sawyer, J., & Cha, R. (2019) · Future Virology · doi:10.2217/fvl-2019-0091
More is better: influenza vaccines in patients with rheumatoid arthritis
Falsey, A. R. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30112-2
Self-citationImpfungen für das Immungedächtnis – immer wieder oder einmalig?
Lehmann, C. (2022) · Der Internist · doi:10.1007/s00108-022-01324-w
Influenza vaccination in the elderly
&NA; (1990) · Inpharma Weekly · doi:10.2165/00128413-199007580-00008
Chiu, D. C. S. (2022) · Quality of life in Asia · doi:10.1007/978-981-19-3061-4_7
Guerra, A., Cossio, J., Enciso, J. M., Alcocer, A., Gómez-Álvarez, E., Meaney, E., Palomo‐Piñón, S., & Alcocer, L. A. (2023) · Cardiovascular and Metabolic Science · doi:10.35366/110250
Immune Response and Infections in the Elderly
Bryan, N. B., & Sarwari, A. R. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316676325.011
de Lima, G. T. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2020.tde-13092023-110326
Chronic Obstructive Pulmonary Disease, Part 5: Clinical Pearls for Comorbid COPD
Clifford, K. M., Klein, M. S., Courtney, L. A., Dyke, A. V., Sigler, M., & Basinger, R. L. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.404 · Cited by 1
Bashir, S., Wilson, M., Ashiru-Oredope, D. A. I., & Murdan, S. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-35811-1_9
Veroniki, A. A., Thirugnanasampanthar, S. S., Konstantinidis, M., Dourka, J., Ghassemi, M., Neupane, D., Khan, P. A., Nincic, V., Corry, M., Robson, R. C., et al. (2023) · medRxiv · doi:10.1101/2023.11.29.23299123
High Time for High-Dose Flu Vaccines in Cardiovascular Patients?
Behrouzi, B., & Udell, J. A. (2025) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011857
McCullers, J. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00191-6 · Cited by 1
Langhoff, A. C. F., Johansen, N. D., Modin, D., Janstrup, K. H., Bartholdy, K. V., Espersen, C., Nealon, J., Samson, S., Loiacono, M. M., Harris, R. C., et al. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70177
“With four times the antigen content of standard-dose influenza vaccines, the high-dose influenza vaccine has demonstrated superior immunogenicity and superior efficacy against lab-confirmed influenza infection [11].”
Maxwell, J., Joyner, J. A., Norton, J. E., Knapp, W., Wang, I., Swaminathan, G., Monslow, M. A., & Citron, M. P. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2689208
“These include increasing antigen doses, 6 using potent adjuvants, 7 creating novel formulations, 8 and altering routes of administration.”
Treanor, J. J. (2026) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_19-3
Self-citationState-of-the-art of the high dose influenza vaccine in Spain
Sanz-Muñoz, I., Avellà, J. M. F., Barroso-Santos, P. J., & Eiros, J. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843611
High-Dose Influenza Vaccination in Mexican Adults Aged 60 Years and Older.
Martin, R., Galván‐Oseguera, H., Alcocer, L., Palomo‐Piñón, S., Muñoz, E. G. C., Muñoz, J. M., Diaz, E., Mendoza, A. C., & Álvarez‐López, H. (2026) · Annals of Clinical Hypertension · doi:10.29328/journal.ach.1001043
High-dose influenza vaccination in older adults: Reconciling trial evidence for policy
Cai, L., Hu, X., Lin, L., & Tong, Y. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100221
Escandón-Vargas, K., Tang, S. Q., Forschmiedt, J., Low, K., Lin, B. C., Wang, J. L., Castro, M., Narpala, S., Serebryannyy, L., Anderson, J. L., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag494
Park, H.-S., Yin, A., Zhou, W., Wenstedt, E. F. E., Jedlicka, A., Dziedzic, A., Werner, A., Fenstermacher, K., Li, H., Shea, P. J., et al. (2026) · mBio · doi:10.1128/mbio.01435-26 · Cited by 2
“…aged 65+ years, antibody titers to both the standard and high-dose seasonal influenza vaccine are also greater in females than males (15, 16), with greater season-to-season durability of immunity against influenza among older females than males, particularly in response to H3N2 and IBV…”
High dose inactivated influenza virus vaccine antibody response
Handel, A. (2025) · ImmPort · doi:10.21430/m3donlp073
Metadata
- Authors
- Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J.
- Affiliations
- University of Rochester Medicine (US)
- St. Louis VA Medical Center (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-15
- Volume
- 200
- Issue
- 2
- Pages
- 172-180
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2164949714
- Cited by
- 388
- References
- 22
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 12 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 25 · 2019: 33 · 2018: 25 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 32 · 2013: 34 · 2012: 24
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- high-dose influenza vaccine, standard-dose influenza vaccine, immunogenicity, older adults, seroconversion, hemagglutination inhibition titers, trivalent inactivated influenza vaccine, vaccine dose comparison, local adverse reactions, seroprotection rate
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Viral, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.